QUANTA THERAPEUTICS
QUANTA THERAPEUTICS logo

Quanta Therapeutics is a clinical-stage biotechnology company developing novel therapies for the treatment of neurodegenerative diseases. The company's lead product candidate, QUANTA-101, is a small molecule inhibitor of the protein kinase GSK-3β that is currently in Phase 2 clinical trials for the treatment of Alzheimer's disease. Quanta Therapeutics is also developing a pipeline of other potential therapies for the treatment of Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.